AI and brain scans aim to predict who is at risk for suicide

NCT ID NCT07484906

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to enroll 150 people at different risk levels for self-harm to understand how brain activity and blood markers relate to suicide risk. Participants would have received brain scans, blood tests, and three different treatments (neurofeedback, transcranial magnetic stimulation, and psilocybin therapy). The goal was to use artificial intelligence to find patterns that could accurately identify high-risk individuals. However, the study was withdrawn before any participants were enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18-69 years old 2. Have been on a stable psychiatric medication regimen for at least four weeks prior to study participation. Exclusion Criteria: 1. A prior history of other central nervous system disease or any history of seizures; 2. history of psychotic disorders (e.g., schizophrenia, schizoaffective disorder, bipolar disorder type I); 3. history of current or recent (within two years) substance/alcohol use disorder, with the exception of tobacco use disorder; 4. meet criteria for Very High risk of suicide, or require inpatient hospital-level care for psychiatric reasons at time of consent, to reduce exacerbation of risk of harm to self during study; 5. presence of any implanted metal or electrical device (e.g. pacemaker); 6. recent medical hospitalization (within three weeks); 7. any condition that would prevent the participant from completing the protocol, such as significant agitation; 8. appointment of a legal representative or treatment guardian; 9. any ongoing litigation related to a health condition; 10. any other contraindication to exposure to strong magnetic fields or MRI, such as severe claustrophobia; 11. pregnancy or lactation; 12. a family history of schizophrenia or schizoaffective disorder (first or second degree relatives), or bipolar disorder type 1 (first degree relatives), to reduce risk of exacerbation of an undiagnosed psychotic condition; 13. other medical conditions that would preclude safe participation in the trial (e.g., decompensated heart failure); 14. starting or planning to start psychotherapy or changing the frequency or intensity of existing psychotherapy during the trial (current psychotherapy can be continued provided the frequency and intensity has been stable for ≥2 months prior to screening); 15. membership in a vulnerable population (minors, prisoners); 16. any contraindication for blood draws.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Suicidal ideation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression post-traumatic stress disorder Suicidal Ideation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.